转化生长因子-β与肿瘤

doi:10.3760/cma.j.issn.1673-422X.2015.01.011

国际肿瘤学杂志 ›› 2015, Vol. 42 ›› Issue (1): 43-45.doi: 10.3760/cma.j.issn.1673-422X.2015.01.011

转化生长因子-β与肿瘤

唐乃玲, 郭志, 杨雪玲

300060 天津医科大学肿瘤医院介入治疗肿瘤科国家肿瘤临床医学研究中心天津市肿瘤防治重点实验室

收稿日期:2014-06-18 修回日期:2014-08-04 出版日期:2015-01-08 发布日期:2015-01-07
通讯作者: 郭志 E-mail:cjr.guozhi.@vip.163.com
基金资助:
天津市科技计划（12ZCDZSY17200）；中国博士后科学基金（2014M551032）；天津医科大学肿瘤医院博士启动基金（B1313）

Transforming growth factor-β and tumor

Tang Nailing, Guo Zhi, Yang Xueling

Department of Interventional Therapy, Tianjin Medical University Cancer Institute and Hospital; National Clinical Research Center of Cancer; Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China

Received:2014-06-18 Revised:2014-08-04 Online:2015-01-08 Published:2015-01-07
Contact: Guo Zhi E-mail:cjr.guozhi.@vip.163.com

摘要/Abstract

摘要： 研究表明，转化生长因子β（TGFβ）在肿瘤初期通过抑制肿瘤细胞增殖、去分化以及促进细胞凋亡等发挥抑癌作用。但在肿瘤发展中，随着TGFβ通路相关分子发生变异以及TGFβ自身发生转变，其促癌作用逐步显现。TGFβ通路抑制剂具有抗肿瘤作用，但其临床疗效及不良反应仍有待观察。

关键词: 转化生长因子β, 肿瘤, 抑制剂

Abstract: Many studies show that transforming growth factorβ (TGFβ) can suppress tumor by inhibiting proliferation and dedifferentiation of cells and promoting cell apoptosis at early stage. But during the progression of tumor, its tumorpromoting action will be more and more obvious with the variation of TGFβ itself and its signal path. TGFβ signal path inhibitors have antitumor activity, but the clinical effects and side effects still need to be observed.

Key words: Transforming growth factor β, Neoplasms, Inhibitors

唐乃玲, 郭志, 杨雪玲. 转化生长因子-β与肿瘤[J]. 国际肿瘤学杂志, 2015, 42(1): 43-45.

Tang Nailing, Guo Zhi, Yang Xueling. Transforming growth factor-β and tumor[J]. Journal of International Oncology, 2015, 42(1): 43-45.

参考文献

［1］ Kalluri R, Weinberg RA. The basics of epithelialmesenchymal transition［J］. J Clin Invest, 2009, 119(6): 1420-1428. ［2］ Yilmaz M, Christofori G. EMT, the cytoskeleton, and cancer cell invasion［J］. Cancer Metastasis Rev, 2009, 28(1-2): 15-33. ［3］ Nieto MA. The ins and outs of the epithelial to mesenchymal transition in health and disease［J］. Annu Rev Cell Dev Biol, 2011, 27: 347-376. ［4］ Lamouille S, Derynck R. Cell size and invasion in TGFbetainduced epithelial to mesenchymal transition is regulated by activation of the mTOR pathway［J］. J Cell Biol, 2007, 178(3): 437-451. ［5］ Shin JA, Hong OK, Lee HJ, et al. Transforming growth factorβ induces epithelial to mesenchymal transition and suppresses the proliferation and transdifferentiation of cultured human pancreatic duct cells［J］. J Cell Biochem, 2011, 112(1): 179-188. ［6］ Mu Y, Gudey SK, Landstrm M. NonSmad signaling pathways［J］. Cell Tissue Res, 2012, 347(1): 11-20. ［7］ Nam JS, Terabe M, Kang MJ, et al. Transforming growth factor beta subverts the immune system into directly promoting tumor growth through interleukin17［J］. Cancer Res, 2008, 68(10): 3915-3923. ［8］ Nam JS, Terabe M, Mamura M, et al. An antitransforming growth factor beta antibody suppresses metastasis via cooperative effects on multiple cell compartments［J］. Cancer Res, 2008, 68(10): 38353843. ［9］ Drabsch Y, ten Dijke P. TGFβ signaling in breast cancer cell invasion and bone metastasis［J］. J Mammary Gland Biol Neoplasia, 2011, 16(2): 97-108. ［10］ Hu Z, Zhang Z, Guise T, et al. Systemic delivery of an oncolytic adenovirus expressing soluble transforming growth factor-β receptorⅡFc fusion protein can inhibit breast cancer bone metastasis in a mouse model［J］. Hum Gene Ther, 2010, 21(11): 1623-1629. ［11］ Lonning S, Mannick J, McPherson JM. Antibody targeting of TGFβ in cancer patients［J］. Curr Pharm Biotechnol, 2011, 12(12): 2176-2189. ［12］ Schlingensiepen KH, Jaschinski F, Lang SA, et al. Transforming growth factorbeta 2 gene silencing with trabedersen (AP 12009) in pancreatic cancer［J］. Cancer Sci, 2011, 102(6): 1193-1200. ［13］ Hau P, Jachimczak P, Schlingensiepen R, et al. Inhibition of TGFbeta2 with AP 12009 in recurrent malignant gliomas: from preclinical to phase Ⅰ/Ⅱ studies［J］. Oligonucleotides, 2007, 17(2): 201-212. ［14］ Bogdahn U, Hau P, Stockhammer G, et al. Targeted therapy for highgrade glioma with the TGFβ2 inhibitor trabedersen: results of a randomized and controlled phase Ⅱb study［J］. Neuro Oncol, 2011, 13(1): 132-142. ［15］ Strimpakos AS, Syrigos KN, Saif MW. Novel agents and new combination treatments on phase Ⅰ studies on solid tumors and pancreatic cancer［J］. JOP, 2012, 13(4): 345-348. ［16］ Tanaka H, Shinto O, Yashiro M, et al. Transforming growth factor β signaling inhibitor, SB431542, induces maturation of dendritic cells and enhances antitumor activity［J］. Oncol Rep, 2010, 24(6): 1637-1643. ［17］ Takeuchi K, Abe M, Hiasa M, et al. TgfBeta inhibition restores terminal osteoblast differentiation to suppress myeloma growth［J］. PLoS One, 2010, 5(3): e9870. ［18］ Connolly EC, Saunier EF, Quigley D, et al. Outgrowth of drugresistant carcinomas expressing markers of tumor aggression after longterm TβRⅠ/Ⅱ kinase inhibition with LY2109761［J］. Cancer Res, 2011, 71(6): 2339-2349. ［19］ Serizawa M, Takahashi T, Yamamoto N, et al. Combined treatment with erlotinib and a transforming growth factorβ type Ⅰ receptor inhibitor effectively suppresses the enhanced motility of erlotinibresistant nonsmallcell lung cancer cells［J］. J Thorac Oncol, 2013, 8(3): 259-269. ［20］ Rodon J, Carducci MA, SepulvedaSanchez JM, et al. Firstinhuman dose study of the Novel transforming growth factorβ receptor Ⅰ kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and glioma［J］. Clin Cancer Res, 2014, In press. ［21］ Saito RA, Watabe T, Horiguchi K, et al. Thyroid transcription factor1 inhibits transforming growth factorbetamediated epithelialtomesenchymal transition in lung adenocarcinoma cells［J］. Cancer Res, 2009, 69(7): 2783-2791. ［22］ Bi X, Pohl NM, Qian Z, et al. Decorinmediated inhibition of colorectal cancer growth and migration is associated with Ecadherin in vitro and in mice［J］. Carcinogenesis, 2012, 33(2): 326-330.

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲. 血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	袁健, 黄燕华. Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[4]	陈红健, 张素青. 血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[5]	郭泽浩, 张俊旺. PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[6]	张百红, 岳红云. 新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[7]	许凤琳, 吴刚. EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[8]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[9]	张蕊, 褚衍六. 基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[10]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[11]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[12]	刘静, 刘芹, 黄梅. 基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[13]	杨琳, 路宁, 温华, 张明鑫, 朱琳. 炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[14]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[15]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志. 宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.

转化生长因子-β与肿瘤

Transforming growth factor-β and tumor

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价